Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancer https://www.biorxiv.org/content/10.1101/2023.04.22.537922v1?med=mas
Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancer https://www.biorxiv.org/content/10.1101/2023.04.22.537922v1?med=mas